

AVELLINO COMPANY BACKGROUND

Company Overview

Avellino is a precision medicine company focused on making a global impact in genetics to diagnose rare and challenging diseases, bringing new levels of efficiency and effectiveness to drug development, and making therapies more targeted to individual needs. The company is integrating advanced diagnostics, gene therapies, molecular diagnostics, and AI-driven data processing into a genetic discovery and testing platform that is purpose-built to deliver more accurate, timely, and actionable patient insights to healthcare practices worldwide. This novel technology platform enables Avellino to empower healthcare providers and patients with the precise information needed for early detection, as well as disease therapy and management.

The company's initial development and commercialization efforts resulted in the launch of two diagnostic tests for the detection of eye diseases: AvaGen and the Universal Test, the world's first genetic tests for keratoconus and a range of corneal diseases that affect the vision of millions of people worldwide. The AvaGen platform will be further enhanced, through additional research and development, to include genetic diagnostic testing for other eye conditions, such as presbyopia, uveitis, cataracts, myopia, macular degeneration, and more.

Meanwhile, in response to the global public health call for effective and rapid COVID-19 diagnostics, Avellino quickly developed and received FDA approval under its Emergency Use Authorization for its AvellinoCoV2 test. Focused on early, accurate detection of the COVID-19 disease as well as all various mutant strains of the Coronavirus, rt-PCR genetic tests of this type can quickly detect the Coronavirus in patients who are not yet displaying symptoms.

Company Facts

Category	Biotechnology research & development, and clinical genetic diagnostics
Specialization	Genetic diagnostics, Gene therapies, and Genetic data
Established	2008
Founder	Gene Lee
Employees	80
Headquarters	Menlo Park, California, USA
International Div.	Korea, Japan, China, United Kingdom
Intellectual Property	3 patents, and 4 patents pending for genetic diagnostics and therapeutics
Company Websites	www.Avellino.com and www.AvellinoCoronaTest.com
Company Contact	+1 (650) 396-3741

Current Products

AvaGen Test The first and only commercially available genetic diagnostic test of its kind for eye care. AvaGen detects risk factors for keratoconus and the presence of corneal dystrophies. It provides eye care practitioners with information to support disease monitoring, preventive strategies, and the initiation of vision therapies – in many cases before symptoms are present.

Continued...



Avellino Lab USA, Inc.

1505 Adams Dr, Menlo Park, CA 94025 | 650-396-3741 | Avellino.com and AvellinoCoronaTest.com

AVELLINO COMPANY BACKGROUND

...Continued

AvaGen Test

- High complexity CLIA laboratory certification in the United States
- Identifies markers across 75 genes related to keratoconus
- Identifies more than 70 mutations of the TGFBI gene that comprise the universe of TGFBI-related corneal dystrophies


Universal Test

Genetic test identifying the presence of TGFBI mutations that are responsible for 5 TGFBI corneal dystrophies.

AvellinoCoV2 Test

FDA-approved rapid genetic test that detects asymptomatic and symptomatic COVID-19 (Coronavirus) in about 4 to 7 hours using highly accurate viral RNA N-gene targets.

Avellino Milestones



Leadership

Gene Lee	President and Chairman
Thomas Kim	Chief Strategy Officer and Corporate Secretary
Connie Chao-Shern, PhD, CLS	Chief Laboratory Officer
Scott Korney	Chief Operating Officer
Eric Bernabei	Chief Sales and Marketing Officer
John Hong	Chief People Officer Interim General Counsel
Stanley Chang	Chief Information Officer



Avellino Lab USA, Inc.

1505 Adams Dr, Menlo Park, CA 94025 | 650-396-3741 | Avellino.com and AvellinoCoronaTest.com